Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 29.99 Million USD | -31.38% |
| 2021 | 43.71 Million USD | 86.79% |
| 2020 | 23.4 Million USD | -22.28% |
| 2019 | 30.1 Million USD | 12.04% |
| 2018 | 26.87 Million USD | 30.47% |
| 2017 | 20.59 Million USD | 150.4% |
| 2016 | 8.22 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 869 Thousand USD | -85.46% |
| 2023 Q2 | 5.97 Million USD | -4.55% |
| 2023 Q1 | 6.26 Million USD | -15.59% |
| 2022 Q1 | 7.42 Million USD | -25.53% |
| 2022 FY | 29.99 Million USD | -31.38% |
| 2022 Q3 | 7.41 Million USD | -7.68% |
| 2022 Q2 | 8.02 Million USD | 8.15% |
| 2022 Q4 | 7.42 Million USD | 0.11% |
| 2021 FY | 43.71 Million USD | 86.79% |
| 2021 Q2 | 6.26 Million USD | -9.16% |
| 2021 Q1 | 6.89 Million USD | 18.48% |
| 2021 Q4 | 9.96 Million USD | -52.81% |
| 2021 Q3 | 21.12 Million USD | 237.07% |
| 2020 Q1 | 6.55 Million USD | 15.24% |
| 2020 Q4 | 5.82 Million USD | 0.54% |
| 2020 Q3 | 5.79 Million USD | 10.75% |
| 2020 FY | 23.4 Million USD | -22.28% |
| 2020 Q2 | 5.23 Million USD | -20.23% |
| 2019 Q3 | 7.39 Million USD | -10.54% |
| 2019 Q1 | 8.75 Million USD | 25.7% |
| 2019 FY | 30.1 Million USD | 12.04% |
| 2019 Q4 | 5.68 Million USD | -23.07% |
| 2019 Q2 | 8.26 Million USD | -5.63% |
| 2018 Q2 | 4.57 Million USD | -40.56% |
| 2018 FY | 26.87 Million USD | 30.47% |
| 2018 Q4 | 6.96 Million USD | 5.26% |
| 2018 Q3 | 6.62 Million USD | 44.79% |
| 2018 Q1 | 7.69 Million USD | 44.78% |
| 2017 Q1 | 5.84 Million USD | 0.0% |
| 2017 Q2 | 3.99 Million USD | -31.58% |
| 2017 Q3 | 5.48 Million USD | 37.18% |
| 2017 Q4 | 5.31 Million USD | -3.15% |
| 2017 FY | 20.59 Million USD | 150.4% |
| 2016 FY | 8.22 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -4435.927% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -223.619% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 55.332% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -89.314% |
| Better Therapeutics, Inc. | 38.26 Million USD | 21.612% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 26.287% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -142.021% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 11.379% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 12.859% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 72.348% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -2921.024% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 7.966% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 36.119% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2369.194% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -50.422% |
| Molecular Templates, Inc. | 63.09 Million USD | 52.461% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -115.288% |
| NexImmune, Inc. | 28.16 Million USD | -6.481% |
| Orgenesis Inc. | 45.75 Million USD | 34.452% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -16.945% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -40753.492% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -85.77% |
| Scopus BioPharma Inc. | 11.71 Million USD | -156.025% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 92.568% |
| Statera Biopharma, Inc. | 28.82 Million USD | -4.036% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -58.45% |
| Trevena, Inc. | 38.41 Million USD | 21.92% |
| Vaxxinity, Inc. | 56.05 Million USD | 46.49% |
| Vaccinex, Inc. | 23.45 Million USD | -27.875% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -2764.721% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 40.834% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -312.296% |